Prostaglandin FP receptor agonists in the treatment of glaucoma and ocular hypertension: a literature review

References

• Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081–2090.
   PubMed Web of Science ®Google Scholar
• Bodh SA, Kumar V, Raina UK, et al. Inflammatory glaucoma. Oman J Ophthalmol. 2011;4(1):3–9. doi: 10.4103/0974-620X.77655
   PubMedGoogle Scholar
• McMonnies CW. Glaucoma history and risk factors. J Optom. 2017;10(2):71–78. doi: 10.1016/j.optom.2016.02.003
   PubMedGoogle Scholar
• Goel M, Picciani RG, Lee RK, et al. Aqueous humor dynamics: a review. Open Ophthalmol J. 2010;4:52–59. doi: 10.2174/1874364101004010052
   PubMedGoogle Scholar
• Gabelt BT, Kaufman PL. Changes in aqueous humor dynamics with age and glaucoma. Prog Retin Eye Res. 2005;24(5):612–637. doi: 10.1016/j.preteyeres.2004.10.003
   PubMed Web of Science ®Google Scholar
• Aihara M. Prostanoid receptor agonists for glaucoma treatment. Jpn J Ophthalmol. 2021;65(5):581–590. doi: 10.1007/s10384-021-00844-6
   PubMed Web of Science ®Google Scholar
• Alexander SP, Kelly E, Marrion NV, et al. The concise guide to pharmacology 2017/18: overview. Br J Pharmacol. 2017;174(Suppl 1):S1–s16. doi: 10.1111/bph.13883
   PubMedGoogle Scholar
• Woodward DF, Liang Y, Krauss AH. Prostamides (prostaglandin-ethanolamides) and their pharmacology. Br J Pharmacol. 2008;153(3):410–419. doi: 10.1038/sj.bjp.0707434
   PubMed Web of Science ®Google Scholar
• Sharif NA, Kelly CR, Crider JY. Agonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor. J Ocul Pharmacol Ther. 2002;18(4):313–324. doi: 10.1089/10807680260218489
   PubMed Web of Science ®Google Scholar
• Wirta DL, Kuwayama Y, Lu F, et al. Phase 2b, randomized, 3-month, dose-finding study of sepetaprost in patients with primary open-angle glaucoma or ocular hypertension: the ANGEL study. J Ocul Pharmacol Ther. 2022;38(3):240–251. doi: 10.1089/jop.2021.0077
   PubMed Web of Science ®Google Scholar
• Yu L, Ding K, Luo L, et al. Prescribing trends of glaucoma drugs in six major cities of China from 2013 to 2017. PLoS One. 2020;15(1):e0227595. doi: 10.1371/journal.pone.0227595
   PubMed Web of Science ®Google Scholar
• Li T, Lindsley K, Rouse B, et al. Comparative effectiveness of first-line medications for primary open-angle glaucoma: a systematic review and network meta-analysis. Ophthalmology. 2016;123(1):129–140. doi: 10.1016/j.ophtha.2015.09.005
   PubMed Web of Science ®Google Scholar
• Inoue K, Shiokawa M, Higa R, et al. Adverse periocular reactions to five types of prostaglandin analogs. Eye (Lond). 2012;26(11):1465–1472. doi: 10.1038/eye.2012.195
   PubMed Web of Science ®Google Scholar
• Angeli A, Supuran CT. Prostaglandin receptor agonists as antiglaucoma agents (a patent review 2013 - 2018). Expert Opin Ther Pat. 2019;29(10):793–803. doi: 10.1080/13543776.2019.1661992
   PubMed Web of Science ®Google Scholar
• Garhöfer G, Schmetterer L. Nitric oxide: a drug target for glaucoma revisited. Drug Discov Today. 2019;24(8):1614–1620. doi: 10.1016/j.drudis.2019.05.033
   PubMed Web of Science ®Google Scholar
• Nathanson JA, McKee M. Identification of an extensive system of nitric oxide-producing cells in the ciliary muscle and outflow pathway of the human eye. Invest Ophthalmol Vis Sci. 1995;36(9):1765–1773.
   PubMed Web of Science ®Google Scholar
• Doganay S, Evereklioglu C, Turkoz Y, et al. Decreased nitric oxide production in primary open-angle glaucoma. Eur J Ophthalmol. 2002;12(1):44–48. doi: 10.1177/112067210201200109
   PubMed Web of Science ®Google Scholar
• Galassi F, Renieri G, Sodi A, et al. Nitric oxide proxies and ocular perfusion pressure in primary open angle glaucoma. Br J Ophthalmol. 2004;88(6):757–760. doi: 10.1136/bjo.2003.028357
   PubMed Web of Science ®Google Scholar
• Mincione F, Nocentini A, Supuran CT. Advances in the discovery of novel agents for the treatment of glaucoma. Expert Opin Drug Discov. 2021;16(10):1209–1225. doi: 10.1080/17460441.2021.1922384
   PubMed Web of Science ®Google Scholar
• Fingeret M, Gaddie IB, Bloomenstein M. Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open-angle glaucoma and ocular hypertension. Clin Exp Optom. 2019;102(6):541–550. doi: 10.1111/cxo.12853
   PubMed Web of Science ®Google Scholar
• Cavet ME, DeCory HH. The role of nitric oxide in the intraocular pressure lowering efficacy of Latanoprostene Bunod: review of nonclinical studies. J Ocul Pharmacol Ther. 2018;34(1–2):52–60. doi: 10.1089/jop.2016.0188
   PubMed Web of Science ®Google Scholar
• Muenster S, Lieb WS, Fabry G, et al. The ability of nitric oxide to lower intraocular pressure is dependent on guanylyl cyclase. Invest Ophthalmol Vis Sci. 2017;58(11):4826–4835. doi: 10.1167/iovs.17-22168
   PubMed Web of Science ®Google Scholar
• Sagara T, Gaton DD, Lindsey JD, et al. Topical prostaglandin F2alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch Ophthalmol. 1999;117(6):794–801. doi: 10.1001/archopht.117.6.794
   PubMedGoogle Scholar
• Garcia GA, Ngai P, Mosaed S, et al. Critical evaluation of latanoprostene bunod in the treatment of glaucoma. Clin Ophthalmol. 2016;10:2035–2050. doi: 10.2147/OPTH.S103985
   PubMedGoogle Scholar
• Weinreb RN, Scassellati Sforzolini B, Vittitow J, et al. Latanoprostene bunod 0.024% versus timolol maleate 0.5% in subjects with open-angle glaucoma or ocular hypertension: the APOLLO study. Ophthalmol. 2016;123(5):965–973. doi: 10.1016/j.ophtha.2016.01.019
   PubMed Web of Science ®Google Scholar
• Medeiros FA, Martin KR, Peace J, et al. Comparison of latanoprostene bunod 0.024% and timolol maleate 0.5% in open-angle glaucoma or ocular hypertension: the LUNAR study. Am J Ophthalmol. 2016;168:250–259. doi: 10.1016/j.ajo.2016.05.012
   PubMed Web of Science ®Google Scholar
• Kawase K, Vittitow JL, Weinreb RN, et al. Long-term safety and efficacy of latanoprostene bunod 0.024% in Japanese subjects with open-angle glaucoma or ocular hypertension: the JUPITER study. Adv Ther. 2016;33(9):1612–1627. doi: 10.1007/s12325-016-0385-7
   PubMed Web of Science ®Google Scholar
• A study to evaluate the effect of Latanoprostene bunod ophthalmic solution 0.024% on episcleral venous pressure and outflow facility in participants with ocular hypertension U.S. National Library of Medicine; 2022. Available from: https://clinicaltrials.gov/study/NCT04140279
   Google Scholar
• Walters TR, Kothe AC, Boyer JL, et al. A randomized, controlled Comparison of NCX 470 (0.021%, 0.042%, and 0.065%) and latanoprost 0.005% in patients with open-angle glaucoma or ocular hypertension: the dolomites study. J Glaucoma. 2022;31(6):382–391. doi: 10.1097/IJG.0000000000002030
   PubMed Web of Science ®Google Scholar
• Impagnatiello F, Toris CB, Batugo M, et al. Intraocular pressure-lowering activity of NCX 470, a novel nitric oxide-donating bimatoprost in preclinical models. Invest Ophthalmol Vis Sci. 2015;56(11):6558–6564. doi: 10.1167/iovs.15-17190
   PubMed Web of Science ®Google Scholar
• Nicox Reports Achieving primary Objective in Mont Blanc, the first phase 3 glaucoma trial for NCX 460 [press release]. Nicox SA2022.
   Google Scholar
• Neufeld AH, Hernandez MR, Gonzalez M. Nitric oxide synthase in the human glaucomatous optic nerve head. Arch Ophthalmol. 1997;115(4):497–503. doi: 10.1001/archopht.1997.01100150499009
   PubMed Web of Science ®Google Scholar
• Pasquale LR. Vascular ad autonomic dysregulation in primary open-angle glaucoma. Curr Opin Ophthalmol. 2016;27(2):94–101. doi: 10.1097/ICU.0000000000000245
   PubMed Web of Science ®Google Scholar
• Calabrese V, Mancuso C, Calvani M, et al. Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nat Rev Neurosci. 2007;8(10):766–775. doi: 10.1038/nrn2214
   PubMed Web of Science ®Google Scholar
• Bastia E, Sgambellone S, Lucarini L, et al. NCX 470 restores ocular hemodynamics and retinal cell physiology after ET-1-Induced Ischemia/Reperfusion injury of optic nerve and retina in rabbits. J Ocul Pharmacol Ther. 2022;38(7):496–504. doi: 10.1089/jop.2022.0004
   PubMed Web of Science ®Google Scholar
• El-Nimri NW, Moghimi S, Penteado RC, et al. Comparison of the effects of Latanoprostene bunod and timolol on retinal blood vessel density: a randomized clinical trial. Am J Ophthalmol. 2022;241:120–129. doi: 10.1016/j.ajo.2022.04.022
   PubMed Web of Science ®Google Scholar
• Sharif NA, Odani-Kawabata N, Lu F, et al. FP and EP2 prostanoid receptor agonist drugs and aqueous humor outflow devices for treating ocular hypertension and glaucoma. Exp Eye Res. 2023;229:109415. doi: 10.1016/j.exer.2023.109415
   PubMed Web of Science ®Google Scholar
• Yamane S, Karakawa T, Nakayama S, et al. IOP-Lowering effect of ONO-9054, a novel dual agonist of prostanoid EP3 and FP receptors, in monkeys. Invest Ophthalmol Vis Sci. 2015;56(4):2547–2552. doi: 10.1167/iovs.14-16181
   PubMed Web of Science ®Google Scholar
• Liu P, Wang F, Song Y, et al. Current situation and progress of drugs for reducing intraocular pressure. Ther Adv Chronic Dis. 2022;13:20406223221140392. doi: 10.1177/20406223221140392
   Web of Science ®Google Scholar
• Sirinek PE, Lin MM. Intracameral sustained release bimatoprost implants (durysta). Semin Ophthalmol. 2022;37(3):385–390. doi: 10.1080/08820538.2021.1985145
   PubMed Web of Science ®Google Scholar
• Shirley M. Bimatoprost implant: First approval. Drugs Aging. 2020;37(6):457–462. doi: 10.1007/s40266-020-00769-8
   PubMed Web of Science ®Google Scholar
• Medeiros FA, Walters TR, Kolko M, et al. Phase 3, randomized, 20-month study of bimatoprost implant in open-angle glaucoma and ocular hypertension (ARTEMIS 1). Ophthalmology. 2020;127(12):1627–1641. doi: 10.1016/j.ophtha.2020.06.018
   PubMed Web of Science ®Google Scholar
• Mansberger SL, Conley J, Verhoeven RS, et al. Interim analysis of Low dose ENV515 travoprost XR with 11 month duration followed by dose Escalation and 28 day efficacy evaluation of high dose ENV515. Invest Ophthalmol Visual Sci. 2017;58(8):2110–.
   Web of Science ®Google Scholar
• Navratil T, Garcia A, Verhoeven RS, et al. Advancing ENV515 (travoprost) intracameral implant into clinical development: nonclinical evaluation of ENV515 in support of first-time-in-human phase 2a clinical study. Invest Ophthalmol Visual Sci. 2015;56(7):5706–.
   PubMedGoogle Scholar
• Katz LJ, Sarkisian SR, Voskanyan LA, et al. Results of the prospective, randomized, controlled, multicenter phase 3 trials of the travoprost intraocular implant versus topical timolol. Invest Ophthalmol Visual Sci. 2023;64(8):4296–.
   Web of Science ®Google Scholar
• Craven ER, Walters T, Christie WC, et al. 24-month phase I/II clinical trial of bimatoprost sustained-release implant (bimatoprost SR) in glaucoma patients. Drugs. 2020;80(2):167–179. doi: 10.1007/s40265-019-01248-0
   PubMed Web of Science ®Google Scholar
• Basha M, Paauw J, Sarkisian SR, et al. Longevity of IOP control Post single bimatoprost implant injection in a phase 3b study. Invest Ophthalmol Visual Sci. 2022;63(7):3492–.
   Web of Science ®Google Scholar
• Vantipalli S, Sall KN, Stein E, et al. Evaluation of the safety and efficacy of OTX-TP, an intracanalicular travoprost insert, for the treatment of patients with open-angle glaucoma or ocular hypertension: a phase 3 study. Invest Ophthalmol Visual Sci. 2020;61(7):3488–.
   Web of Science ®Google Scholar
• Utkhede D, William R. Improving retention rates for sustained therapeutic delivery through punctal plugs. Invest Ophthalmol Visual Sci. 2018;59(9):5675–.
   Web of Science ®Google Scholar
• Brandt JD, Sall K, DuBiner H, et al. Six-month intraocular pressure reduction with a topical bimatoprost ocular insert: results of a phase II randomized controlled study. Ophthalmology. 2016;123(8):1685–1694. doi: 10.1016/j.ophtha.2016.04.026
   PubMed Web of Science ®Google Scholar
• Chen MY, Sall KN, Tepedino M, et al. Patient-reported outcomes of bimatoprost ocular ring in an open-label Extension study in patients with open-angle glaucoma or ocular hypertension. Invest Ophthalmol Visual Sci. 2018;59(9):1231–.
   Web of Science ®Google Scholar
• Human Trial with Novel Glaucoma Treatment Rendered a Clinically Meaningful Efficacy Outcome and Positive Safety and Tolerability Data [press release]. MediPrint Ophthalmics; 2023.
   Google Scholar
• Ciolino JB, Ross AE, Tulsan R, et al. Latanoprost-Eluting Contact Lenses in Glaucomatous Monkeys. Ophthalmology. 2016;123(10):2085–2092. doi: 10.1016/j.ophtha.2016.06.038
   PubMed Web of Science ®Google Scholar
• Baudouin C, Labbé A, Liang H, et al. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29(4):312–334. doi: 10.1016/j.preteyeres.2010.03.001
   PubMed Web of Science ®Google Scholar
• Horwath-Winter J, Thaci A, Gruber A, et al. Long-term retention rates and complications of silicone punctal plugs in dry eye. Am J Ophthalmol. 2007;144(3):441–444. doi: 10.1016/j.ajo.2007.05.019
   PubMed Web of Science ®Google Scholar